Addison's Disease Treatment Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| CAGR | 4.10 % |
| Fastest Growing Market | Asia-Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Addison's Disease Treatment Market Analysis
Addison's Disease Treatment market is projected to register a CAGR of 4.1% during the forecast period (2022 - 2027).
COVID-19 pandemic has significantly impacted Addison's disease, a rare disease treatment market. The rise in COVID-19 cases has led to global healthcare services shifting their resources toward COVID-19 care while impacting patients with rare diseases. According to the Eurordis International Survey in February 2021, rare disease patients seemed to have a worse experience than chronic disease patients due to the pandemic. According to the article titled ' COVID-19 and the endocrine system: exploring the unexplore' published in May 2020, it has been found that the adrenal system is one of the most highly affected organ systems in the body during acute active infection in individuals with COVID-19 infection who require hospitalization. The pandemic led to the shutdown of companies and other non-healthcare businesses. The lack of healthcare services and canceled/postponed appointments result in the underdiagnosis of rare disease patients, negatively impacting the market.
The factors propelling the market's growth are rising incidences of Addison's disease globally, growing awareness regarding adrenal insufficiency, and rising healthcare expenditure in the countries.
The rising incidences of Addison's disease are the key factor driving the market's growth over the forecast period. According to an article "Adrenal Insufficiency in Patients," published in June 2021, it has been found that one in 10,000 newborns are affected by congenital adrenal hyperplasia, an inherited form of primary adrenal insufficiency. In addition, the increasing number of tuberculosis cases is also causing adrenal insufficiency disease among people. According to the statistics published by the Centers for Disease Control and Prevention (CDC) data updated in 2021, around 7,860 cases of tuberculosis were reported in the United States in 2021. In addition, about 13 million in the United States are affected by latent tuberculosis infection.
Similarly the article titled ' Adrenal Insufficiency and Addinon's Disease ' published in July 2020 mentioned that Addison's disease can affect all age groups, but the most common onset was at 30-50 years of age. The annual incidence of Addinson's disease was 4 in 1,000,000 peope in Western populations. Such incidence of addison's disease is expected to drive the demand for the effective treatmnet, thereby contributing to the growth of the market.
However, the high costs associated with the treatment medications, the lack of awareness among people regarding Addison's disease, and the inability to diagnose the disease early are likely to hinder the market's growth.
Addison's Disease Treatment Market Trends
This section covers the major market trends shaping the Addison's Disease Treatment Market according to our research experts:
Oral Route is Expected to Have the Significant Market Share
The factors propelling the growth of the oral segment are easy to top consume and are better replacement therapy for the disease. The most common oral drugs used for the treatment include corticosteroids such as hydrocortisone, prednisone, or methylprednisone, and fludrocortisone acetate, which replaces the cortisol and aldosterone in the body, which the body lacks to produce. According to the article titled 'Hydrocortisone' published in May 2020, oral hydrocortisone and fludrocortisone are found to have the potential to simulate the physiological serum cortisol level in the body.
In addition, the increasing number of tuberculosis cases is also causing adrenal tuberculosis, leading to adrenal insufficiencies in patients, likely increasing the demand for disease treatment. Adrenal insufficiency also occurs due to direct glandular involvement, extra-adrenal infection, and anti-tuberculosis medication. Moreover, the company focusing on developing oral medications for treating patients with Addison's disease is also likely to increase the market growth over the forecast period. For instance, in February 2022, Diurnal announced that the first patient was dosed in its phase II European clinical trial of modified-release hydrocortisone for treating people with adrenal insufficiency (AI), also known as Addison's disease.
Thus the above-mentioned factors are expected to drive the growth of the studied segment during the te forecast period.
North America is Expected to Have the Significant Market Share
North America is anticipated to have a significant share, owing to the factors such as increasing disease instances in the region, growing demand for new generation technologically integrated advanced therapeutic drugs for swift and long-term therapy, and a well-established healthcare infrastructure.
The increasing number of tuberculosis or adrenal tuberculosis cases causes adrenal insufficiency in patients by destructing the adrenal cortex and hypertrophy of the adrenal glands with caseating granulomas, thus, increasing the demand for better treatment in the region. Adrenal insufficiency also occurs due to direct glandular involvement, extra-adrenal infection, or anti-tuberculosis medication. According to the statistics published by the Centers for Disease Control and Prevention (CDC), in 2021, it has been found that 35.8% of Non-Hispanic Asian persons, 29.7% of Hispanic people, and 11% of Non-Hispanic White people have tuberculosis disease in the United States.
Moreover, the increasing research and development activities and increasing focus of the companies in developing treatments for Addison's disease is further boosting the market's growth in the region. For instance, in January 2022, Antares Pharma announced positive results from a Phase I study for ATRS-1902 for adrenal crisis. ATRS-1902 was developed to treat acute adrenal insufficiency, an adrenal crisis, in adults and adolescents.
Thus the above mentioned factors are expected to drive the growth of the market in this region.
Addison's Disease Treatment Industry Overview
Addison's disease treatment market is moderately competitive with many players. The players focus on developing drugs to treat the disease and withhold their position in the market. Some key players are Bristol-Myers Squibb Company, Merck KGaA, Sandoz International GmbH, Pfizer Inc., and Takeda Pharmaceutical Company Limited.
Addison's Disease Treatment Market Leaders
-
Takeda Pharmaceutical Company Limited
-
Merck KGaA
-
Sandoz International GmbH
-
Pfizer Inc.
-
Bristol-Myers Squibb Company
*Disclaimer: Major Players sorted in no particular order
Addison's Disease Treatment Market News
- In April 2022 Diurnal Group extended its distribution agreement with Er-Kim to include the distribution and marketing of Alkindi(hydrocortisone granules in capsules for opening) and Efmody (hydrocortisone modified-release hard capsule) in Greece, Cyprus and Malta.
- In January 2022, Antares Pharma announced that the United States Food and Drug Administration had granted Fast Track designation for ATRS-1902 for adrenal crisis rescue in adults and adolescents using the company's Vai novel proprietary auto-injector platform to deliver a stable liquid formulation of hydrocortisone.
Addison's Disease Treatment Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 Rising Incidences of Addison's Disease
- 4.2.2 Growing Awareness about the Addison's Disease and Rising Healthcare Expenditure
-
4.3 Market Restraints
- 4.3.1 Inability to Diagnose the Disease in Early Stages
- 4.3.2 High Costs Associated with the Treatment
-
4.4 Porter's Five Forces Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD million)
-
5.1 By Drug Class
- 5.1.1 Glucocorticoid
- 5.1.2 Mineralocorticoid
- 5.1.3 Others
-
5.2 By Route of Administration
- 5.2.1 Oral
- 5.2.2 Parenteral
- 5.2.3 Others
-
5.3 By Diagnosis
- 5.3.1 Laboratory Testing
- 5.3.2 Imaging Testing
-
5.4 By End-user
- 5.4.1 Hospitals
- 5.4.2 Homecare
- 5.4.3 Specialty Clinics
- 5.4.4 Others
-
5.5 Geography
- 5.5.1 North America
- 5.5.2 Europe
- 5.5.3 Asia-Pacific
- 5.5.4 Middle East and Africa
- 5.5.5 South America
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 Bristol-Myers Squibb Company
- 6.1.2 Merck KGaA
- 6.1.3 Sandoz International GmbH
- 6.1.4 Pfizer Inc.
- 6.1.5 Takeda Pharmaceutical Company Limited
- 6.1.6 GlaxoSmithKline plc
- 6.1.7 Abbott
- 6.1.8 Amgen Inc.
- 6.1.9 Bayer AG
- 6.1.10 Eli Lilly and Company
- 6.1.11 Biogen
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablityAddison's Disease Treatment Industry Segmentation
As per the report's scope, Addison's disease is a rare disorder in which the adrenal cortex fails to produce adequate glucocorticoids and mineralocorticoids to meet metabolic demands (primary adrenocortical insufficiency). The loss or primary dysfunction of the adrenal glands. The Global Addison's Disease Treatment Market is segmented by drug class ( Glucocorticoid, Mineralocorticoid, and Others), route of administration ( Oral, Parenteral, and Others), diagnosis (Laboratory Testing and Imaging Testing), end-user (Hospitals, Homecare, Specialty Clinics, and Others) and Geography (North America, Europe, Asia-Pacific, Middle East, and Africa, South America). The report offers the value (USD million) for the above segments.
| By Drug Class | Glucocorticoid |
| Mineralocorticoid | |
| Others | |
| By Route of Administration | Oral |
| Parenteral | |
| Others | |
| By Diagnosis | Laboratory Testing |
| Imaging Testing | |
| By End-user | Hospitals |
| Homecare | |
| Specialty Clinics | |
| Others | |
| Geography | North America |
| Europe | |
| Asia-Pacific | |
| Middle East and Africa | |
| South America |
Addison's Disease Treatment Market Research FAQs
What is the current Global Addison's Disease Treatment Market size?
The Global Addison's Disease Treatment Market is projected to register a CAGR of 4.10% during the forecast period (2024-2029)
Who are the key players in Global Addison's Disease Treatment Market?
Takeda Pharmaceutical Company Limited, Merck KGaA, Sandoz International GmbH, Pfizer Inc. and Bristol-Myers Squibb Company are the major companies operating in the Global Addison's Disease Treatment Market.
Which is the fastest growing region in Global Addison's Disease Treatment Market?
Asia-Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Global Addison's Disease Treatment Market?
In 2024, the North America accounts for the largest market share in Global Addison's Disease Treatment Market.
What years does this Global Addison's Disease Treatment Market cover?
The report covers the Global Addison's Disease Treatment Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Global Addison's Disease Treatment Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Addisons Disease Therapeutics Industry Report
Statistics for the 2023 Addisons Disease Therapeutics market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Addisons Disease Therapeutics analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
